Sprout Pharmaceuticals Inc.
Seeking to renew a failed drug, and women’s sex lives
This article was originally published in Start Up
Executive Summary
The backers of Sprout Pharmaceuticals Inc. are convinced the start-up has a drug candidate that can help women who’ve lost interest in sex feel desire again: flibanserin, a daily pill that interacts with receptors in the CNS. It was originally developed by Boehringer Ingelheim, which failed to win FDA approval in 2010 for its use in treating hypoactive sexual desire disorder, but Sprout is optimistic the clinical development work it has since put into the compound will help it win regulators’ approval.
You may also be interested in...
Women’s Health: Moving Beyond Gynecology To Sexuality
Big Pharma’s exodus from women’s health has created opportunities for biotech start-ups, which hope to tap into potentially huge markets. Profiles of Evestra Pharmaceuticals, S1 Biopharma, and Sprout Pharmaceuticals.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.